Erythema nodosum, after Medigen vaccination against COVID-19?
Hui-Te Hsu, Hsuan-An Su, Yu-Chia Chen
Journal of the Formosan Medical Association · 2022
doi:10.1016/j.jfma.2021.10.002 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Erythema nodosum, after Medigen vaccination against COVID-19?Dear Editor, The Medigen vaccine (MVC-COV1901) was launched in August, 2021 in Taiwan as the first Taiwanese-developed vaccine against COVID-19.1 However, its real-world effect and safety remain largely unknown.Herein, we report a cutaneous eruption post Medigen vaccination.A 27-year-old otherwise healthy man presented 3 days after the first dose of the vaccine with fever, malaise, headache, myalgia in extremities, nausea, abdominal discomfort, swelling of the ankles, and painful skin rash on the legs.He denied recent drug exposure or contact history.Physical examination revealed several tender erythematous deep-seated nodules on bilateral lower legs (Fig. 1A).Laboratory tests showed elevated C-reactive protein level (8.97 mg/dl) and prolonged erythrocyte sedimentation rate (22 mm/h).Complete blood count, hepatic and renal panels were within normal limits.Antinuclear antibody and anti-neutrophil cytoplasmic antibody were not detected.A SARS-CoV-2 rapid antigen test showed negative result.A tests for anti-streptolysin O antibody and QuantiFERON-TB Glod test were negative.Chest X-ray unraveled no pathological findings.Differential diagnoses included erythema nodosum (EN), neutrophilic dermatosis, and cutaneous vasculitis.A skin biopsy was performed.Histology demonstrated subcutaneous septal panniculitis with lymphocytic infiltrates and Miescher's granulomas (Fig. 1B).No other known risk factors for EN were identified in our patient, such as infections, sarcoidosis, malignancy, or other drug exposure.Therefore, EN associated with the Medigen vaccination was suspected.The patient was treated with oral prednisolone, colchicine, and topical fluocinonide, and the EN showed significant resolution after 10 days.The second dose of Medigen was not suggested.To our knowledge, this is the first case of EN after a single dose of Medigen vaccination against COVID-19.The phase 2 trial of Medigen vaccine disclosed good safety profile with mostly mild adverse events and none serious adverse event.
Abstract licence: CC BY-NC-ND
References5
5 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.